EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Interaction with patients and consumers: Training session questionnaire results

Presented by: Nathalie Bere
Patient interaction – stakeholder and Communication Division

An agency of the European Union

Background

- Questionnaire sent to all participants who attended the training session held in December 2013
- Specific questions to be answered by choosing among 6 rating grades; from “Agree”, to “Disagree”. Each question allowed for additional comments.
- Request for comments / suggestions for improvement for each training topic
- Final text box for general comments and suggestions
- 27 responses received
- The results are shown in the graphs below



- Very well organised
- Extremely impressive; a model to be followed by every public institution!
- Very good, as always
- I was really impressed by the arrangements and support for travel/accommodation, meeting room and the welcome.
- Excellent. When we could not leave because of the fog the travel bureau was most helpful
- Everything was OK with the exception of 2.15hrs travel with two metros from Heathrow to Canary Wharf
- Would be helpful to be able to book hotel & airfare pretty soon, when the dates of the next meeting are known


The presentations given were clear and understandable
25
20
15
10
5
0
20
3
1
1
1 (Agree)
2
3
4
5
6 (Disagree)



- Very well presented with additional notes



- As a relative newcomer I find this difficult to judge, for me the content of the meeting was rich and enlightening.
- It would be helpful if there was a full list of abbreviations used during the day.
- More examples on how to comment on a PL would have been appreciated.



- After some topics I felt the discussion was stopped prematurely. For the future I would suggest to take note of the topics that generated more lively exchanges and adjust the allocated times for those?
- Although the program was tight, there was time for discussion, although it would be advisable that the time of presentations and discussions would be more equally divided. The purpose of the meeting being to be informed and to exchange views, effort should be made for more discussion time.
- That's always the most difficult item in such meetings, but the chairs did this excellent.



- I am glad to have attended the meeting
- I had it before



- The training will help me a lot in recruiting additional experts/patients (at least to try to!).



- The training was comprehensive and sufficient time was allocated.
- I believe the duration was just enough.
- The training session was perfect!
- The timing was just right.
- Just fine.
- Everyone stayed alert to the end of the meeting, which indicates the duration of the meeting was good.
- For me it was very good timing, not too short, not too long. I already had some previous experience which helped me organise my thoughts and understanding of the EMA work.
- The training session was adequate but more sessions are advisable during the year to cover the complexity of medicines authorization/pricing/circulation.
- As a general info session there are always subjects which have your attention more. Time is too short to go deep in the subjects which could be seen as a missed opportunity.
- For those of us familiar with EMA work it was perfect, but for newcomers it must have been very demanding and exhausting.



- Great to always learn something new
- Very good

Comments or suggestions for improvement

Session 1; Overview of EMA and centralised procedure

- Very comprehensive.
- More understanding is needed on medicines' pricing.

Session 2; Scientific Advice procedures

- Very well chaired however some presentations restricted time for questions.
- Need for more understanding of the procedure & how it impacts on authorisation.

Session 3; Scientific Advisory Group (SAG) meetings

- Role of patients and their real life experience with medicines.

Session 4; Review of information to patients

- Very comprehensive.
- Better understanding of need for lay terms info to patients, similar Cochrane policy.

Session 5; Pharmacoviglance

- Awareness activities to inform patients about AEs and that they may directly report to their national regulator

Session 6; Practical aspects

- It would be helpful if this subject is done before a break as during the break people may try it out. Especially for practical purposes.

Comments or suggestions for improvement

General comments:

- It was very well organised.
- I enjoyed the conferences over the 2 days and found them sometimes challenging, as it was my first time, but informative and educational - I loved them!
- Thank you. I feel I have been honoured to be present at such meeting. I have learned something and I will learn more with pleasure to help others.
- A very worthwhile day thank you.
- Very nice session!
- I am very pleased to attend these training sessions; they are useful refreshers and also provide an opportunity to meet and network with people of similar interests. Well done to Nicola, Nathalie and all their colleagues for organising this event.
- Breaks were not sufficient to meet but very few participants.

Training for 2014?

2012: New pharmacovigilance legislation;

- Pharmacovigilance Risk Assessment Committee (PRAC);
- Risk management plans/PASSs;
- ADR reporting and signal detection; PSURs; Safety Referrals;
- Impact of PhV legislation on product information.

2013:

- Overview of the EMA and the centralised procedure

Patient involvement in:

- Scientific Advice procedures
- Scientific Advisory Group meetings,

Information to patients:

- review of PLs,
- EPAR summaries
- safety communications

- What is Pharmacovigilance / Impact of pharmacovigilance for patients